A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED February 12, 2021 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »
Arguably, the most challenging step in plasmid manufacturing is cell lysis. Thousands of times larger than a typical small molecule pharmaceutical API, a plasmid is a large circular molecule that most of our clients prefer in the supercoiled form. Several things can go wrong if the lysis step is too harsh. First, the… Read More »
One of the major challenges of plasmid manufacturing is cleaning validation. To avoid excess costs and time, disposable technology can decrease validation needs for both the cleaning and sterilization processes of fixed equipment systems. Disposable materials for use in pharmaceutical manufacturing have come a long way from traditional reusable technology. From pipettes… Read More »
Most companies struggle with how to make cGMP training more fun and exciting. As the Quality Assurance director of a company that provides contract plasmid manufacturing, it seems almost impossible for me to find time to be creative. This year for the “dreaded” cGMP training we played a game – yes, a… Read More »
VGXI Supports Local Girl Scouts in the 2010 Body Forward Challenge The Woodlands, Texas – September 28, 2010 VGXI, a world leader in DNA vaccine contract manufacturing, announced today that it is sponsoring a local Girl Scout chapter in its effort to compete in the First® LEGO® League, an international robotics competition… Read More »
The Woodlands, Texas – April 30, 2010 VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today that Henry Hebel, VGXI’s Chief Operating Officer, participated in a vidcast interview at INTERPHEX New York discussing pandemic preparedness and universal flu vaccine development. The interview took place in front of… Read More »
New Orleans, LA – March 2, 2010 – VGXI, Inc., a leading provider of DNA plasmid manufacturing and development services, announced today at the 2010 DNA Vaccines Conference the expansion of its state-of-the-art cGMP plasmid manufacturing facility in The Woodlands, TX. “This expansion nearly doubles the size of our current facility putting… Read More »
San Diego, CA – May 26, 2009 – VGXI Inc., a leading manufacturer of DNA plasmids and creator of AIRMIXTM Technology, announced today that the company will present at the 2009 American Society of Gene Therapy 12th Annual Meeting at the San Diego Convention Center. The American Society of Gene Therapy… Read More »
GeoVax’s Dr. Harriet Robinson – a key conference speaker on “the State of the Art Session” VGXI Inc.’s Robert J. Juba – speaker on Manufacturing a High Concentration Multi-Component DNA Vaccine Las Vegas, NV – December 8, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for… Read More »
VGXI, Inc. today announced the execution of a Master Product Sale Agreement to supply plasmid between its parent company, VGX International, and BioCancell Therapeutics. BioCancell is a biopharmaceuticals corporation specializing in the development of Patient-Oriented, Targeted Therapy for the treatment of numerous types of cancer. Products under the Agreement will be manufactured… Read More »
Senesco Technologies, Inc. ("Senesco" or the "Company") (AMEX:SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) (“VGXI”) to supply the plasmid portion of the Company’s combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A. Senesco has previously reported positive preclinical in vivo results using… Read More »
VGX Pharmaceuticals announced today that it has submitted two separate investigational new drug (IND) applications to the U.S. Food and Drug Administration (FDA) for Phase I clinical studies of VGX-3100 and VGX-3400. Both candidate vaccines are based on VGX’s SynCon™ vaccine technology, and they have been developed using VGX’s integrated DNA Vaccines… Read More »
VGX Pharmaceuticals (VGX) today announced that the Company has signed a multi-year supply agreement to provide plasmid DNA to support the ongoing toxicology and clinical trials of the United Kingdom Cystic Fibrosis Gene Therapy Consortium comprising over 80 scientists and clinicians in Edinburgh, London and Oxford dedicated to the search for effective… Read More »
Sign Up
For more information